Cargando…

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

Background: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK inhibitors have been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Helei, Sun, Dantong, Liu, Kewei, Jiang, Man, Liu, Dong, Zhu, Jingjuan, Zhou, Na, Cong, Jing, Zhang, Xiaochun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511621/ https://www.ncbi.nlm.nih.gov/pubmed/31190983 http://dx.doi.org/10.2147/CMAR.S190098

Ejemplares similares

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Chemotherapy Alters the Phylogenetic Molecular Ecological Networks of Intestinal Microbial Communities
por: Cong, Jing, et al.
Publicado: (2019)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
por: Qin, Kang, et al.
Publicado: (2020)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
por: Hou, Helei, et al.
Publicado: (2019)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma
por: Sun, Dantong, et al.
Publicado: (2023)

Advancement in research and therapy of NF1 mutant malignant tumors
por: Tao, Junyan, et al.
Publicado: (2020)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
por: Omar, N.E., et al.
Publicado: (2021)

Adverse events of targeted therapies approved for women's cancers
por: Saint-Ghislain, Mathilde, et al.
Publicado: (2021)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring
por: Donzelli, Alberto
Publicado: (2019)

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis
por: Guo, Chang-Ying, et al.
Publicado: (2019)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
por: Tao, Junyan, et al.
Publicado: (2020)

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
por: Karimian, Zahra, et al.
Publicado: (2020)

The role of RICTOR amplification in targeted therapy and drug resistance
por: Zhao, Deze, et al.
Publicado: (2020)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Surveillance of serious adverse events following immunization in resource poor settings
por: Breugelmans, Gabrielle J, et al.
Publicado: (2011)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

A Cancer Patient’s Experience With a Rare But Serious Adverse Event
por: RayChaudhury, Amlan
Publicado: (2019)

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
por: Hosoda, Tomohiro, et al.
Publicado: (2019)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
por: Sun, Dantong, et al.
Publicado: (2020)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
por: Bauer, Scott, et al.
Publicado: (2021)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
por: Duprey, Matthew S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dtnijl97hbfqseq2i1mqetiop2